David A. Siegel Hille Vax, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q4 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Hille Vax, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 41,200 shares of HLVX stock, worth $73,336. This represents 0.0% of its overall portfolio holdings.
Number of Shares
41,200
Previous 23,300
76.82%
Holding current value
$73,336
Previous $41,000
104.88%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding HLVX
# of Institutions
75Shares Held
35.5MCall Options Held
0Put Options Held
0-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.6MShares$18.9 Million1.3% of portfolio
-
Tang Capital Management LLC San Diego, CA4.92MShares$8.76 Million0.75% of portfolio
-
Black Rock Inc. New York, NY2.09MShares$3.72 Million0.0% of portfolio
-
Franklin Resources Inc San Mateo, CA1.96MShares$3.48 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY1.88MShares$3.35 Million0.1% of portfolio
About HilleVax, Inc.
- Ticker HLVX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 33,427,200
- Market Cap $59.5M
- Description
- HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.